Astrazeneca Pharma India Ltd

As the world undergoes constant evolution, AstraZeneca Pharma India Limited (AstraZeneca) is constantly redefining the standard of care by offering life-enhancing and life-saving treatments. We are committed to transforming outcomes for our patients, increasing access to healthcare and making healthcare systems more resilient, while growing the success of our Company. Pushing the boundaries of science, the Company is continuously transforming healthcare with its unwavering dedication to scientific excellence. AstraZeneca's success stems from its focus on research and development, investing significantly to drive groundbreaking discoveries and reimagine the future of medicine.

As a leading pharmaceutical company, AstraZeneca is leveraging its scientific expertise to provide accessible and effective treatment for its patients globally. Collaborating with experts worldwide, the Company tackles the most pressing medical challenges across diverse therapeutic areas. In oncology, the Company has made remarkable strides, developing innovative treatments that target the underlying mechanisms of cancer.

As the burden of disease grows and the population ages, we believe that science is key to helping unlock the answers to healthcare challenges.

With a relentless pursuit of innovative solutions and dedication to improving global health, AstraZeneca shapes the future of medicine, forging a path towards a healthier and brighter world for all.

AstraZeneca's spirit of bringing science-led innovations for one and all extends beyond medicine as it actively engages in sustainability and ethical practices. By aligning its operations with social responsibility, the Company ensures its scientific advancements create a sustainable and equitable future.

Managing Director's Statement implemented our strategy of Growth Through Innovation. Our leading pipeline and numerous approvals for innovative medicines demonstrate our commitment to benefiting people, society, and the planet.

At AstraZeneca India, we are dedicated to transforming healthcare by unlocking the power of science. Our commitment to innovation is evident in the progress of our pipeline, with nine new medicines and indication approvals received last year. This positions us optimally to bring innovative therapies faster and closer to patients in India. Supported by various states, peers, and industry stakeholders, we strive to ensure no patient is left behind in the therapy areas we serve. Our dedication extends to sustainably contributing to the well-being of people, society, and the planet.

The financial year 2023-24 has been marked by continued strong performance and the successful execution of our Growth Through

Innovation strategy. Our entity achieved a remarkable growth of 29%, reaching 1,330 crore. This includes 90 crore from the sale of services to related parties and 35 crore from other income. Our pharmaceutical product sales saw a strong increase of 28% reaching 1,205 crore. In our key therapy areas, we experienced significant revenue growth: Oncology increased by 43%, Respiratory & Immunology rose by 24%, Cardiovascular, Renal & Metabolism grew by 8%.

This exceptional performance reflects the trust and confidence placed in us by the healthcare ecosystem in India.

As a science-led biopharmaceutical company, we at AstraZeneca are trusted and valued for consistently pushing the boundaries of science to deliver life-changing medicines. India's healthcare sector is transitioning towards collaboration, breaking silos between pharma companies, academia, healthcare providers, and research institutions.

This collective approach is crucial for improving patient outcomes, driving innovation, and speeding up the delivery of new treatments. Our India Innovation Hub under the A.Catalyst Network exemplifies this commitment, connecting AstraZeneca with collaborators to address healthcare challenges.

We are committed to creating healthier societies by building strategic alliances and collaborating with partners to tackle major health challenges. Our goal is to co-create tailored healthcare solutions and improve access to care by identifying barriers and providing more people with equitable access to healthcare.

For instance, we have collaborated with Qure.ai, an organisation developing deep learning algorithms for radiology image interpretation for lung cancer. With the support of the Karnataka government, we have successfully deployed this solution in 19 district hospitals across the state, enabling doctors to screen patients for lung cancer through X-rays and ensuring that at-risk patients gain access to necessary therapies much faster. Recently, we signed an MoU with the State Government of Goa to accelerate lung cancer detection, emphasising early detection and intervention in combating lung diseases.

We have also formed strategic partnerships to enhance access and make healthcare more equitable. In oncology, we signed an MoU with Rajiv Gandhi Cancer Institute and Research Centre (RGCI&RC), Delhi, to establish a centre of excellence for subsidised, high-quality Next-Generation

Sequencing (NGS) molecular panel testing for individuals diagnosed with lung cancer.

Additionally, we partnered with Roche Diagnostics India to enhance diagnostics for breast cancer patients, focusing on streamlining HER2 diagnostics with advancements in the field.

In respiratory care, we have established centres of excellence across India to standardise the management of severe asthma patients. Notable facilities at Bramha Kumaris Hospital in Mumbai and Manipal Hospital in Goa aim to redefine the diagnosis and treatment of severe asthma. Furthermore, we entered an exclusive partnership with Mankind Pharma for the distribution of AstraZeneca's Symbicort (budesonide and formoterol fumarate dihydrate), an inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combination, in India. This partnership aims to accelerate access and maximise the potential of our asthma drug and the Turbuhaler, an efficient device for consistently delivering a higher proportion of respirable particles.

We are dedicated to bringing innovative medicines to India quickly and strategically improving access across the country. I am delighted to share the progress of our business with you. AstraZeneca's values of ‘Putting Patients First & Doing the Right Thing' have driven our growth across our focused therapy areas.

Our achievements are a direct result of the skills and capabilities of our people. I am delighted to share that 89% of our workforce believes we are a great place to work. We are committed to creating an inclusive environment and offer continuous learning and development opportunities.

We offer cross-country immersion roles to help our people develop cross-cultural leadership and build global networks. Our recognition as a Great Place To Work^? for six consecutive years is a testament to our engaged and motivated workforce. We rank highly among inclusive and best companies for women.

Sustainability is fundamental to building a healthy future for the people, society, and the planet. By using a science-led approach and acting with integrity, we are transforming healthcare and making a positive impact. Sustainability is embedded into everything we do, from the lab to the patient.

Our greatest contribution to human health remains our medicines and ensuring a future where people have access to affordable, sustainable healthcare. We are advancing a health equity strategy to enable more equitable global health outcomes.

I extend my gratitude to all the teams at AstraZeneca for contributing to our success in FY 2023-24 and for the impact we have created for people, society, and the planet. It is a great time to bring innovative drugs to India, and we are committed to harnessing the power of science to deliver life-changing medicines to ensure no patient is left behind!